AZTA

Azenta Inc
NASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES

Key Statistics

Market Cap
$1.27B
P/E Ratio
EPS
$-2.41
Beta
1.37
52W High
$41.73
52W Low
$15.93
50-Day MA
$23.51
200-Day MA
$28.09
Dividend Yield
Profit Margin
-29.10%
Forward P/E
29.07
PEG Ratio
0.53

About Azenta Inc

Azenta Inc. is a premier provider of sample management solutions and life science tools, dedicated to enhancing laboratory efficiencies within the biotechnology and pharmaceutical industries. The company excels in innovative automation and comprehensive biorepository services, facilitating faster drug discovery while ensuring adherence to stringent regulatory standards. With a forward-looking strategy that leverages advanced storage technologies and strategic partnerships, Azenta is uniquely positioned to seize growth opportunities in the expanding global life sciences market. Its commitment to pioneering scientific research through sophisticated innovations underscores its potential appeal to institutional investors seeking exposure in the dynamic life sciences sector.

Official WebsiteUSAFY End: September

Fundamentals

Revenue (TTM)$596.48M
Gross Profit (TTM)$264.42M
EBITDA$36.72M
Operating Margin-10.60%
Return on Equity-6.81%
Return on Assets-0.64%
Revenue/Share (TTM)$12.99
Book Value$33.73
Price-to-Book0.81
Price-to-Sales (TTM)2.13
EV/Revenue1.571
EV/EBITDA25.57
Quarterly Earnings Growth (YoY)8778.00%
Quarterly Revenue Growth (YoY)1.00%
Shares Outstanding$46.09M
Float$40.60M
% Insiders1.00%
% Institutions110.42%

Historical Volatility

HV 10-Day
44.30%
HV 20-Day
41.06%
HV 30-Day
44.16%
HV 60-Day
77.65%
HV Rank
21.4%

Volatility is currently expanding

Analyst Ratings

Consensus ($27.80 target)
1
Strong Buy
2
Buy
3
Hold

Latest News

Azenta Completes Sale of B Medical Systems

BURLINGTON, Mass., July 8, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the completion of the previously disclosed sale of its B Medical Systems business to Thelema S.

PRNewsWire7/8/2026Neutral
Azenta, Inc. (AZTA) Securities Fraud Investigation - Levi & Korsinsky

Azenta, Inc. reaffirmed 3%-5% organic revenue growth and 300 basis points of margin expansion in February 2026 -- then cut both targets three months later after recording a $149 million goodwill impairment. NEW YORK, May 27, 2026 /PRNewswire/ -- Shareholders who purchased Azenta, Inc. (NASDAQ: AZTA) stock lost significant value after the Company slashed its FY 2026 guidance on May 5, 2026 -- reversing projections it had publicly reaffirmed just three months earlier.

PRNewsWire5/27/2026Neutral
Investors in Azenta, Inc. (AZTA) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today

New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Azenta, Inc. (NASDAQ: AZTA) ("Azenta, Inc.") concerning potential violations of the federal securities laws. On February 4, 2026, CEO John Marotta told investors Azenta was "entering the year well positioned for continued success" and reaffirmed FY 2026 guidance of 3%-5% organic revenue growth with approximately 300 basis points of adjusted EBITDA margin expansion.

Newsfile Corp5/25/2026Neutral
Azenta, Inc. (AZTA) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AZENTA, INC. (AZTA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmi.

Business Wire5/22/2026Neutral
Securities Fraud Investigation Into Azenta, Inc. (AZTA) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON AZENTA, INC. (AZTA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About?On May 5, 2026, Azenta released its second quarter 2026 financial results, missing.

Business Wire5/22/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AZTA and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 7/29/2026